EA201591405A1 - Спиролактамные модуляторы nmda-рецептора и их применение - Google Patents
Спиролактамные модуляторы nmda-рецептора и их применениеInfo
- Publication number
- EA201591405A1 EA201591405A1 EA201591405A EA201591405A EA201591405A1 EA 201591405 A1 EA201591405 A1 EA 201591405A1 EA 201591405 A EA201591405 A EA 201591405A EA 201591405 A EA201591405 A EA 201591405A EA 201591405 A1 EA201591405 A1 EA 201591405A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nmda
- spirolactam
- application
- receptor modulators
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Описаны соединения, обладающие повышенной эффективностью модулирования активности NMDA-рецептора. Указанные соединения предусмотрены для применения при лечении патологических состояний, таких как депрессия и родственные расстройства. Описаны также перорально доступные композиции и другие фармацевтически приемлемые формы доставки соединений, включая внутривенные композиции.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361757942P | 2013-01-29 | 2013-01-29 | |
PCT/US2014/013639 WO2014120800A1 (en) | 2013-01-29 | 2014-01-29 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201591405A1 true EA201591405A1 (ru) | 2017-05-31 |
Family
ID=50071824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591405A EA201591405A1 (ru) | 2013-01-29 | 2014-01-29 | Спиролактамные модуляторы nmda-рецептора и их применение |
Country Status (16)
Country | Link |
---|---|
US (2) | US9708335B2 (ru) |
EP (1) | EP2951185B1 (ru) |
JP (1) | JP2016506962A (ru) |
KR (1) | KR20150110784A (ru) |
CN (1) | CN105308049A (ru) |
AU (1) | AU2014212501A1 (ru) |
BR (1) | BR112015018094A2 (ru) |
CA (1) | CA2899191A1 (ru) |
EA (1) | EA201591405A1 (ru) |
ES (1) | ES2618421T3 (ru) |
IL (1) | IL240164A0 (ru) |
MX (1) | MX2015009785A (ru) |
PE (1) | PE20151436A1 (ru) |
PH (1) | PH12015501598A1 (ru) |
SG (1) | SG11201505862TA (ru) |
WO (1) | WO2014120800A1 (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101769999B1 (ko) | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Nmda 수용체 조절제 및 그의 용도 |
AU2014212490A1 (en) | 2013-01-29 | 2015-07-30 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
CN105308049A (zh) | 2013-01-29 | 2016-02-03 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
SG11201505942YA (en) | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
EP3514158B1 (en) | 2013-01-29 | 2022-10-12 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
CN105229010A (zh) * | 2013-01-29 | 2016-01-06 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
EP3152213B1 (en) | 2014-06-04 | 2018-10-31 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
WO2016044323A1 (en) | 2014-09-15 | 2016-03-24 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
WO2016126869A1 (en) | 2015-02-04 | 2016-08-11 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists |
JP6876625B2 (ja) | 2015-06-01 | 2021-05-26 | リューゲン ホールディングス (ケイマン) リミテッド | Nr2bnmdaレセプターアンタゴニストとしての3,3−ジフルオロピペリジンカルバメート複素環式化合物 |
CN108779148A (zh) * | 2016-02-01 | 2018-11-09 | 诺雷克斯股份有限公司 | 用于合成二吡咯烷肽化合物的方法 |
CN109415372B (zh) | 2016-05-19 | 2021-01-15 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
EP3490994B8 (en) | 2016-08-01 | 2024-03-13 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
WO2018026779A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
US10918637B2 (en) | 2016-08-01 | 2021-02-16 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
SG11201900558RA (en) * | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
WO2018026798A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
WO2019152685A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and methods of using same |
US11578072B2 (en) * | 2018-01-31 | 2023-02-14 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
WO2019152688A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
WO2019152696A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
PE20211455A1 (es) * | 2018-01-31 | 2021-08-05 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
CN111018746A (zh) * | 2019-12-16 | 2020-04-17 | 山东金城柯瑞化学有限公司 | 一种氨曲南主环合成中间体n-苄氧羰基-l-苏氨酸酰胺的合成方法 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
WO1992007561A1 (fr) | 1990-10-30 | 1992-05-14 | Ss Pharmaceutical Co., Ltd. | Preparation d'un gel anti-inflammatoire et analgesique |
US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
IL127332A0 (en) | 1996-06-07 | 1999-09-22 | Zeneca Ltd | Peptide derivatives |
EP0918859A1 (en) | 1996-08-02 | 1999-06-02 | ZymoGenetics, Inc. | Testis-specific insulin homolog polypeptides |
US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
AU1585999A (en) | 1997-11-12 | 1999-05-31 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
WO2000028090A2 (en) | 1998-11-12 | 2000-05-18 | Nyxis, Inc. | Diagnostic assay for cancer |
US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
AU1922301A (en) | 1999-11-17 | 2001-05-30 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
JP2003521247A (ja) | 2000-02-01 | 2003-07-15 | エージーワイ セラピューティクス インコーポレーテッド | Nmda受容体のプロテインチロシンホスファターゼとの相互作用 |
WO2001096606A2 (en) | 2000-06-14 | 2001-12-20 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
JP2004500874A (ja) | 2000-06-22 | 2004-01-15 | ニクシス ニューロセラピーズ インコーポレーティッド | 低酸素症および関連状態の治療のための神経活性ペプチド |
GB0018272D0 (en) | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
US20020142287A1 (en) | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
US20030065138A1 (en) | 2001-03-07 | 2003-04-03 | University Of Utah Research Foundation | Linear gamma-carboxyglutamate rich conotoxins |
AU2002255705A1 (en) | 2001-03-12 | 2002-09-24 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
US20030022253A1 (en) | 2001-07-25 | 2003-01-30 | Nyxis Neurotherapies, Inc. | Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby |
DE60330456D1 (de) * | 2002-07-05 | 2010-01-21 | Targacept Inc | N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
EP1660634A4 (en) | 2003-08-08 | 2009-02-18 | Burnham Inst | P16-mediated regulation of NMDA receptors |
US7662856B2 (en) | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
ATE537153T1 (de) * | 2004-09-09 | 2011-12-15 | Merck Sharp & Dohme | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors |
EP1797073B1 (en) * | 2004-09-13 | 2010-04-14 | Merck Sharp & Dohme Corp. | Bicyclic anilide spirolactam cgrp receptor antagonists |
US20060063707A1 (en) | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
PL1868614T3 (pl) | 2005-03-24 | 2013-01-31 | Univ Emory | Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem |
WO2007025141A2 (en) | 2005-08-26 | 2007-03-01 | Wisconsin Alumni Research Foundation | Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same |
WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
WO2008033464A2 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidinone derivatives for the treatment of disorders of the lipid metabolism |
JP2008188285A (ja) | 2007-02-06 | 2008-08-21 | Bridgestone Corp | バックパッド及び車両用シート |
CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
WO2009105718A1 (en) | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
CN102112442B (zh) | 2008-08-07 | 2014-12-10 | 弗·哈夫曼-拉罗切有限公司 | 制备大环的方法 |
KR101769999B1 (ko) | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Nmda 수용체 조절제 및 그의 용도 |
WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
DE102009001460B4 (de) | 2009-03-11 | 2010-12-02 | Zf Friedrichshafen Ag | Ölbehälter |
US20120178695A1 (en) | 2009-07-02 | 2012-07-12 | Joseph Moskal | Methods of treating neuropathic pain |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
HUE043807T2 (hu) | 2009-10-05 | 2019-09-30 | Univ Northwestern | GLYX Alzheimer-kór, Parkinson-kór vagy Huntington-kór kezelésében történõ alkalmazásra |
KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
CA2789331C (en) | 2010-02-11 | 2017-11-07 | Northwestern University | Secondary structure stabilized nmda receptor modulators and uses thereof |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
KR20190037359A (ko) | 2011-04-27 | 2019-04-05 | 노오쓰웨스턴 유니버시티 | 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 |
CN103635264B (zh) | 2011-06-27 | 2016-06-01 | 皇家飞利浦有限公司 | 超声换能组件及其制造方法 |
CN105308049A (zh) | 2013-01-29 | 2016-02-03 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
SG11201505942YA (en) | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
CN105229010A (zh) | 2013-01-29 | 2016-01-06 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
AU2014212490A1 (en) | 2013-01-29 | 2015-07-30 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
EP3514158B1 (en) | 2013-01-29 | 2022-10-12 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
-
2014
- 2014-01-29 CN CN201480018644.1A patent/CN105308049A/zh active Pending
- 2014-01-29 CA CA2899191A patent/CA2899191A1/en not_active Abandoned
- 2014-01-29 US US14/764,426 patent/US9708335B2/en active Active
- 2014-01-29 EA EA201591405A patent/EA201591405A1/ru unknown
- 2014-01-29 MX MX2015009785A patent/MX2015009785A/es unknown
- 2014-01-29 ES ES14703750.1T patent/ES2618421T3/es active Active
- 2014-01-29 PE PE2015001571A patent/PE20151436A1/es not_active Application Discontinuation
- 2014-01-29 AU AU2014212501A patent/AU2014212501A1/en not_active Abandoned
- 2014-01-29 BR BR112015018094A patent/BR112015018094A2/pt not_active IP Right Cessation
- 2014-01-29 KR KR1020157023269A patent/KR20150110784A/ko not_active Application Discontinuation
- 2014-01-29 JP JP2015556106A patent/JP2016506962A/ja not_active Withdrawn
- 2014-01-29 SG SG11201505862TA patent/SG11201505862TA/en unknown
- 2014-01-29 WO PCT/US2014/013639 patent/WO2014120800A1/en active Application Filing
- 2014-01-29 EP EP14703750.1A patent/EP2951185B1/en active Active
-
2015
- 2015-07-20 PH PH12015501598A patent/PH12015501598A1/en unknown
- 2015-07-27 IL IL240164A patent/IL240164A0/en unknown
-
2017
- 2017-06-16 US US15/625,163 patent/US10316041B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20150368254A1 (en) | 2015-12-24 |
CA2899191A1 (en) | 2014-08-07 |
US20180127430A1 (en) | 2018-05-10 |
PH12015501598A1 (en) | 2015-10-19 |
PE20151436A1 (es) | 2015-10-10 |
EP2951185A1 (en) | 2015-12-09 |
JP2016506962A (ja) | 2016-03-07 |
KR20150110784A (ko) | 2015-10-02 |
US9708335B2 (en) | 2017-07-18 |
SG11201505862TA (en) | 2015-08-28 |
ES2618421T3 (es) | 2017-06-21 |
WO2014120800A1 (en) | 2014-08-07 |
CN105308049A (zh) | 2016-02-03 |
EP2951185B1 (en) | 2016-12-21 |
US10316041B2 (en) | 2019-06-11 |
MX2015009785A (es) | 2016-04-04 |
BR112015018094A2 (pt) | 2017-07-18 |
IL240164A0 (en) | 2015-09-24 |
AU2014212501A1 (en) | 2015-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591405A1 (ru) | Спиролактамные модуляторы nmda-рецептора и их применение | |
EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
EA201591404A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
EA201591402A1 (ru) | Спиролактамные модуляторы nmda-рецептора и их применение | |
EA201591401A1 (ru) | Спиролактамные модуляторы nmda-рецептора и их применение | |
EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
EA201990240A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
EA201591430A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
EA201590881A1 (ru) | Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2 | |
EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201690881A1 (ru) | Соединения-ингибиторы аутотаксина | |
EA201591426A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
EA201492050A1 (ru) | Модуляторы ядерного транспорта и их применение | |
EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
EA201590590A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
EA201391416A1 (ru) | Новые соединения в качестве модуляторов протеинкиназ | |
EA201990425A1 (ru) | Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение | |
EA201591432A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
MX2018009752A (es) | 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b. | |
EA201690582A1 (ru) | Модуляторы фактора в комплемента |